Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
Howe, James R. , Merchant, Nipun B. , Conrad, Claudius , Keutgen, Xavier M. , Hallet, Julie , Drebin, Jeffrey A. , Minter, Rebecca M., Lairmore, Terry C., Tseng, Jennifer F. , Zeh, Herbert J. , Libutti, Steven K. , Singh, Gagandeep , Lee, Jeffrey E. , Kim, Michelle K. , Menda, Yusuf , Hálfdánarson, Þorvarður R. , Chan, Jennifer A. , Pommier, Rodney F. , Kim, Michelle Kang , Halfdanarson, Thorvardur R , Howe, James R , Menda, Yusuf , Lee, Jeffrey E., Hope, Thomas A.

Mayo Clinic

Pancreas | December 19, 2019 | Volume: 49 | Issue: 1 | Pages: 1-33

10.1097/mpa.0000000000001454 | PMID 31856076 Get It

Abstract This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the surgical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The group reviewed a series of questions of specific interest to surgeons taking care of patients with pancreatic neuroendocrine tumors, and for each, the available literature was reviewed. What follows are these reviews for each question followed by recommendations of the panel.
Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study
James, Spencer L , Lucchesi, Lydia R , Bisignano, Catherine, Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Henry, Nathaniel J , McCracken, Darrah, Sylte, Dillon O , Ahmadi, Alireza , Alahdab, Fares , Alipour, Vahid , Andualem, Zewudu , Arabloo, Jalal , Badiye, Ashish , Bagherzadeh, Mojtaba , Banstola, Amrit , Bärnighausen, Till , Barzegar, Akbar , Bayati, Mohsen , Bhaumik, Soumyadeep , Bijani, Ali , Bukhman, Gene , Carvalho, Félix , Crowe, Christopher S. , Dalal, Koustuv , Nasab, Mostafa Dianati, Endries, Aman Yesuf , Fernandes, Eduarda , Fischer, Florian , Fukumoto, Takeshi, Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gilani, Syed Amir , Haagsma, Juanita A., Hostiuc, Sorin , Househ, Mowafa , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Kahsay, Amaha , Kapoor, Neeti , Kasaeian, Amir , Khader, Yousef , Khalil, Ibrahim A, Khan, Ejaz Ahmad , Khazaee-Pool, Maryam , Kokubo, Yoshihiro , Madadin, Mohammed , Majdán, Marek , Maled, Venkatesh , Manafi, Navid , Manafi, Ali, Mangalam, Srikanth , Massenburg, Benjamin B. , Meles, Hagazi Gebre , Menezes, Ritesh G. , Meretoja, Tuomo J , Miazgowski, Bartosz , Miller, Ted R. , Mohammadian-Hafshejani, Abdollah , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Cuong Tat , Nixon, Molly R, Olagunju, Andrew T , Olagunju, Tinuke O , Padubidri, Jagadish Rao , Polinder, Suzanne , Rabiee, Navid , Rahimi‐Movaghar, Vafa , Rawaf, David Laith , Rezapour, Aziz , Rickard, Jennifer , Roro, Elias Merdassa , Roy, Nobhojit , Salamati, Payman, Samy, Abdallah M , Satpathy, Maheswar , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shigematsu, Mika, Tohidinik, Hamid Reza , Valdéz, Pascual , Wijeratne, Tissa , Yisma, Engida , Zaidi, Zoubida , Zhang, Zhi-Jiang, Hay, Simon I , Mokdad, Ali H. , Dianatinasab, Mostafa , Wijeratne, T , Roberts, Nicholas L S , Ahmed, Muktar Beshir , Antonio, Carl Abelardo T. , Daryani, Ahmad , Do, Hoa , Do, Huyen Phuc , Filip, Irina , Fukumoto, Takeshi, Hamidi, Samer , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Khalil, Ibrahim A, Lopez, Alan D , Malekzadeh, Reza , Mohammadpourhodki, Reza , Morrison, Shane D. , Nguyen, Trang Huyen , Rabiee, Mohammad , Radfar, Amir , Rawaf, Salman , Safari‐Faramani, Roya , Salamati, Payman, Sepanlou, Sadaf Ghajarieh , Soheili, Amin , Stokes, Mark Andrew , Tran, Bach Xuan , Zamani, Mohammad , Zhang, Zhi‐Jiang , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | December 19, 2019 | Volume: 26 | Issue: Suppl 2 | Pages: i36-i45

10.1136/injuryprev-2019-043299 | PMID 31857422 Get It

Background Past research has shown how fires, heat and hot substances are important causes of health loss globally. Detailed estimates of the morbidity and mortality from these injuries could help drive preventative measures and improved access to care. Methods We used the Global Burden of Disease 2017 framework to produce three main results. First, we produced results on incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years from 1990 to 2017 for 195 countries and territories. Second, we analysed these results to measure mortality-to-incidence ratios by location. Third, we reported the measures above in terms of the cause of fire, heat and hot substances and the types of bodily injuries that result. Results Globally, there were 8 991 468 (7 481 218 to 10 740 897) new fire, heat and hot substance injuries in 2017 with 120 632 (101 630 to 129 383) deaths. At the global level, the age-standardised mortality caused by fire, heat and hot substances significantly declined from 1990 to 2017, but regionally there was variability in age-standardised incidence with some regions experiencing an increase (eg, Southern Latin America) and others experiencing a significant decrease (eg, High-income North America). Conclusions The incidence and mortality of injuries that result from fire, heat and hot substances affect every region of the world but are most concentrated in middle and lower income areas. More resources should be invested in measuring these injuries as well as in improving infrastructure, advancing safety measures and ensuring access to care.
1308: ELECTRONIC INSULIN INFUSION PROTOCOL WITH LESS FREQUENT GLUCOSE MONITORING IN THE CRITICALLY ILL
Lal, Amos , Katta, Sai , Lee, Jennifer , George, Susan, Trivedi, Nitin , Lal, Amos

Mayo Clinic

Critical Care Medicine | December 18, 2019 | Volume: 48 | Issue: 1 | Pages: 631-631

10.1097/01.ccm.0000645148.79632.fe Get It

National Quality Forum Guidelines for Evaluating the Scientific Acceptability of Risk-adjusted Clinical Outcome Measures
Maddox, Karen E. Joynt , Nerenz, David R. , Cella, David , Kunisch, Joseph, Walters, Ronald S., White, Susan , Lin, Zhenqiu , Glance, Laurent G. , Johnson, Karen , Borah, Bijan J. , Kurlansky, Paul A. , Perloff, Jennifer N. , Stoto, ­Michael A.

Mayo Clinic

Annals of Surgery | December 17, 2019 | Volume: 271 | Issue: 6 | Pages: 1048-1055

10.1097/sla.0000000000003592 | PMID 31850998 Get It

Quality measurement is at the heart of efforts to achieve high-quality surgical and medical care at a lower cost. Without accurate quality measures, it is not possible to appropriately align incentives with quality. The aim of these National Quality Forum (NQF) guidelines is to provide measure developers and other stakeholders with guidance on the standards used by the NQF to evaluate the scientific acceptability of performance measures. Using a methodologically rigorous and transparent process for evaluating health care quality measures is the best insurance that alternative payment plans will truly reward and promote higher quality care. Performance measures need to be credible in order for physicians and hospitals to willingly partner with payers in efforts to improve population outcomes. Our goal in creating this position paper is to promote the transparency of NQF evaluations, improve the quality of performance measurements, and engage surgeons and all other stakeholders to work together to advance the science of performance measurement.
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704
Reyngold, Marsha , Winter, Kathryn, Regine, William F., Abrams, Ross A. , Safran, Howard , Hoffman, John P., Mowat, Rex B., Kessel, Ivan L., DiPetrillo, Thomas A., Chen, Yuhchyau , Ben‐Josef, Edgar , Delouya, Guila , Haddock, Michael G. , Feldman, Marvin, Gaur, Rakesh , Yost, Kathleen J. , Peterson, Richard A. , Sherr, David L., Moughan, Jennifer, Crane, Christopher H. , Hayes, John P. , Narayan, Samir , Suh, John H. , Meyer, Joshua E. , Feldman, Marvin, Peterson, Richard A.

Mayo Clinic

The Oncologist | December 16, 2019 | Volume: 25 | Issue: 3 | Pages: e477-e483

10.1634/theoncologist.2019-0562 | PMID 32162826 Get It

AbstractBackgroundSeveral registry-based analyses suggested a survival advantage for married versus single patients with pancreatic cancer. The mechanisms underlying the association of marital status and survival are likely multiple and complex and, therefore, may be obscured in analyses generated from large population-based databases. The goal of this research was to characterize this potential association of marital status with outcomes in patients with resected pancreatic cancer who underwent combined modality adjuvant therapy on a prospective clinical trial.Materials and MethodsThis is an ancillary analysis of 367 patients with known marital status treated on NRG Oncology/RTOG 97-04. Survival analysis was performed using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model.ResultsOf 367 patients, 271 (74%) were married or partnered and 96 (26%) were single. Married or partnered patients were more likely to be male. There was no association between marital status and overall survival (OS) or disease-free survival (DFS) on univariate (hazard ratio [HR], 1.09 and 1.01, respectively) or multivariate analyses (HR, 1.05 and 0.98, respectively). Married or partnered male patients did not have improved survival compared with female or single patients.ConclusionAncillary analysis of data from NRG Oncology/RTOG 97-04 demonstrated no association between marital and/or partner status and OS or DFS in patients with resected pancreatic cancer who received adjuvant postoperative chemotherapy followed by concurrent external beam radiation therapy and chemotherapy. Clinical trial identification number. NCT00003216.
Proceedings From the Ice Hockey Summit III: Action on Concussion
Smith, Aynsley M., Alford, Patrick A., Aubry, Mark, Benson, Brian W., Brooks, Alison, Burke, Charles J., Eaves, Michael, Eickhoff, Chad, Erredge, Kristen, Fraser, Douglas D. , Giza, Christopher C. , Greenwald, Richard M., Hoshizaki, Blaine, Huston, John , Jorgensen, Janelle, Joyner, Michael J. , Leaf, Matthew, Leddy, John J. , Margarucci, Kevin, Munce, Thayne A. , Prideaux, Cara C. , Roberts, William O. , Shen, Francis X. , Soma, David , Tabrum, Mark, Stuart, Michael, Wethe, Jennifer V. , Whitehead, James R., Wiese‐Bjornstal, Diane M. , Dodick, David, Finnoff, Jonathan, Joyner, Michael, Krause, David, Prideaux, Cara, Wethe, Jennifer, Joyner, Michael J , Wethe, Jennifer V , Alford, Patrick W. , Black, Amanda M. , D’Arcy, Ryan C.N. , Dodick, David W. , Farrell, Kyle , Finnoff, Jonathan T. , Krause, David A. , LaVoi, Nicole M. , Margulies, Susan Sheps , Mihalik, Jason P. , Oeur, Anna , Stuart, Michael J.

Mayo Clinic

Clinical Journal of Sport Medicine | December 16, 2019 | Volume: 31 | Issue: 3 | Pages: e150-e160

10.1097/jsm.0000000000000745 | PMID 31842055 Get It

Objectives: The Ice Hockey Summit III provided updated scientific evidence on concussions in hockey to inform these 5 objectives: (1) describe sport related concussion (SRC) epidemiology; (2) classify prevention strategies; (3) define objective, diagnostic tests; (4) identify treatment; and (5) integrate science and clinical care into prioritized action plans and policy. Methods: Our action plan evolved from 40 scientific presentations. The 155 attendees (physicians, athletic trainers, physical therapists, nurses, neuropsychologists, scientists, engineers, coaches, and officials) voted to prioritize these action items in the final Summit session. Results: To (1) establish a national and international hockey database for SRCs at all levels; (2) eliminate body checking in Bantam youth hockey games; (3) expand a behavior modification program (Fair Play) to all youth hockey levels; (4) enforce game ejection penalties for fighting in Junior A and professional hockey leagues; (5) establish objective tests to diagnose concussion at point of care; and (6) mandate baseline testing to improve concussion diagnosis for all age groups. Conclusions: Expedient implementation of the Summit III prioritized action items is necessary to reduce the risk, severity, and consequences of concussion in the sport of ice hockey.
ASHP Guidelines on Pharmacy Services in Solid Organ Transplantation
Maldonado, Angela Q. , Hall, Reed C., Pilch, Nicole A. , Ensor, Christopher R. , Anders, S., Gilarde, Jennifer, Tichy, Eric M.

Mayo Clinic

American Journal of Health-System Pharmacy | December 13, 2019 | Volume: 77 | Issue: 3 | Pages: 222-232

10.1093/ajhp/zxz291 | PMID 31834928 Get It

Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change
Brondfield, Max N. , Hirose, Ryutaro , Yao, Francis Y. , Mehta, Neil , Mehta, Neil , Dodge, Jennifer L. , Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | December 13, 2019 | Volume: 26 | Issue: 5 | Pages: 662-672

10.1002/lt.25701 | PMID 31833634 Get It

For patients with hepatocellular carcinoma (HCC) listed for liver transplantation (LT), United Network for Organ Sharing (UNOS) enacted policy changes in 2015 to improve equity between HCC and non‐HCC patients. We evaluated the impact of these changes on regional disparities in wait‐list dropout and LT. We included patients in the UNOS database listed with Model for End‐Stage Liver Disease HCC exceptions in long‐wait regions (LWRs), mid‐wait regions (MWRs), and short‐wait regions (SWRs) before these policy changes (era 1, January 1 to December 31, 2013) and after (era 2, October 7, 2015, to October 7, 2016). Cumulative incidence of wait‐list dropout and LT were evaluated using competing risk regression. Median time to LT increased by 3.6 months (3.1 to 6.7 months) in SWRs and 1.3 months (6.9 to 8.2 months) in MWRs (P < 0.001), with a slight decrease in LWRs (13.4 to 12.9 months; P = 0.02). The 2‐year cumulative incidence of dropout increased from 9.7% to 14.8% in SWRs (P = 0.03) and from 18.9% to 22.6% in MWRs (P = 0.18) but decreased in LWRs from 26.7% to 24.8% (P = 0.31). Factors predicting wait‐list dropout included listing in era 2 (hazard ratio [HR], 1.17), in LWRs (HR, 2.56), and in MWRs (HR, 1.91). Regional differences in wait‐list outcomes decreased with policy changes, but HCC patients in SWRs remain advantaged. Recent policy change may narrow these disparities.
Relationship Between Domain-Specific Cognitive Function and Speech-in-Noise Performance in Older Adults: The Atherosclerosis Risk in Communities Hearing Pilot Study
Mamo, Sara K. , Reed, Nicholas S. , Sharrett, A. Richey , Albert, Marilyn , Lin, Frank R. , Coresh, Josef , Mosley, Thomas H. , Knopman, David S. , Deal, Jennifer A.

Mayo Clinic

American Journal of Audiology | December 11, 2019 | Volume: 28 | Issue: 4 | Pages: 1006-1014

10.1044/2019_aja-19-00043 | PMID 31825642 Get It

Purpose The purpose of this study was to investigate associations between performance on a clinical speech-in-noise measure with a comprehensive neurocognitive battery of tests. Method A group of older adults ( N = 250, M age = 77 years, age range: 67.3–89.1 years) enrolled in the Atherosclerosis Risk in Communities Neurocognitive Study took part in the hearing pilot study (2013) that included testing for audiometric thresholds and speech-in-noise performance (Quick Speech-in-Noise Test; Killion, Niquette, Gudmundsen, Revit, & Banerjee, 2004). This research study analyzed the associations between domain-specific cognitive function and speech-in-noise performance after adjusting for hearing thresholds and other demographic and cardiovascular factors. Results Multivariable-adjusted associations were found between all cognitive domains and speech-in-noise performance in the full sample, but the observed associations varied when participants with varying levels of moderate to moderately severe hearing loss were excluded from the analysis. Conclusions The findings are discussed in terms considering the cognitive status of older adults in relation to their speech-in-noise performance during audiological evaluation and implications for aural rehabilitation.
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
Marcath, Lauren A. , Vangipuram, Kiran, Gersch, Christina L. , Rae, James M. , Burness, Monika L. , Griggs, Jennifer J. , Poznak, Catherine Van , Hayes, Daniel F. , Henry, N. Lynn , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Henry, N Lynn , Kidwell, Kelley M. , Lavoie Smith, Ellen M

Mayo Clinic

British Journal of Clinical Pharmacology | December 11, 2019 | Volume: 86 | Issue: 5 | Pages: 880-890

10.1111/bcp.14192 | PMID 31823378 Get It

AimsChemotherapy‐induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold).MethodsGermline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8‐item sensory subscale (CIPN8) of the patient‐reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN‐related treatment disruption.ResultsEPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β‐coefficient = 0.39, 95% confidence interval 0.11–0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild‐type (13.6 h) patients. Total number of missense variants (median = 0, range 0–2) was associated with decreased PN sensitivity (β‐coefficient: −0.42, 95% confidence interval −0.72 to −0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683.ConclusionIsolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.